Over the past 10 years, the introduction of immuno-oncology (IO) therapies has brought about a revolutionary change in the treatment of cancer patients worldwide. Learn how to plan for success and reduce risk when developing novel treatments for patients with cancer.
Advancements in science and technology, combined with unmet patient needs, are driving accelerated timelines and creative pathways for oncology drug development. This white paper explores several areas in protocol design to ensure the best way forward.
Conducting effective clinical trials in hematologic malignancies requires an understanding of a rapidly evolving treatment paradigm. Examine the requirements for effectively and successfully conducting hematologic oncology clinical trials.
The landscape of oncology drug development is undergoing a significant transformation, moving away from the traditional approach of dose selection. Explore strategies for integrating dose finding and optimization into early clinical development.
IQVIA Biotech is a stand-alone business of IQVIA with dedicated teams delivering clinical development solutions for biotech and emerging biopharma customers. Discover why IQVIA Biotech is the CRO partner of choice for biotech companies around the world.
IQVIA Biotech oncology experts will be at ESMO Congress and would be delighted to discuss your oncology drug development program. Click to schedule a meeting or visit us at booth #580.
This website uses cookies to ensure you get the best experience on our website. Learn more
